> Detailanzeige

Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard; Blüher, Matthias; Böhm, Michael; Brosius, Frank; Carr, Richard D.; Ceriello, Antonio; Forst, Thomas; Giorgino, Francesco; Guerci, Bruno; Heerspink, Hiddo J. L.; Itzhak, Baruch; Ji, Linong; Kosiborod, Mikhail; Lalić, Nebojša; Lehrke, Michael; Marx, Nikolaus; Nauck, Michael; Rodbard, Helena W.; Rosano, Giuseppe M. C.; Rossing, Peter; Rydén, Lars; Santilli, Francesca; [...]

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
  • Beteiligte: Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard; Blüher, Matthias; Böhm, Michael; Brosius, Frank; Carr, Richard D.; Ceriello, Antonio; Forst, Thomas; Giorgino, Francesco; Guerci, Bruno; Heerspink, Hiddo J. L.; Itzhak, Baruch; Ji, Linong; Kosiborod, Mikhail; Lalić, Nebojša; Lehrke, Michael; Marx, Nikolaus; Nauck, Michael; Rodbard, Helena W.; Rosano, Giuseppe M. C.; Rossing, Peter; Rydén, Lars; Santilli, Francesca; [...]
  • Erschienen: Springer Science and Business Media LLC, 2022
  • Erschienen in: Cardiovascular Diabetology, 21 (2022) 1
  • Sprache: Englisch
  • DOI: 10.1186/s12933-022-01481-0
  • ISSN: 1475-2840
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractThe 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registrationThe 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org)
  • Zugangsstatus: Freier Zugang